Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.
Adjusted EBITDA totaled $75 million, representing a 48% margin. CEO and Co-Founder Jeff Tangney said revenue and adjusted EBITDA exceeded the high end of the company’s guidance by 3% and 8%, respectively. Doximity also raised its full-year revenue outlook by $6 million while continuing to increase spending on AI infrastructure, safety and product development.
AI usage and clinical-study results
Tangney said Doximity’s clinical AI products reached record usage levels during the quarter. Quarterly active workflow prescribers increased more than 30% year over year, with nearly half using the company’s AI tools in the period. AI prompt volume grew more than 25% sequentially, while usage of Doximity’s AI Scribe note-taking product rose 10-fold in July compared with the prior year, according to the company.
The CEO also highlighted the NOHARM study, an independent evaluation of 24 clinical AI models across 1,100 real-world patient cases conducted by researchers from Stanford and Harvard. Tangney said Doximity Ask had the lowest clinical error rate and highest safety rating among U.S. models in the study. He said Doximity’s model recorded a 4.8% error rate, compared with 13.6% for Anthropic’s Fable 5 model.
Doximity attributed its results to a built-in drug reference that it said is expert-verified for drug dosing and interactions, as well as more than 12,000 physician PeerCheck editors who review and refine AI outputs. Tangney said hospitals are increasingly focused on privacy, data protection and the potential liability associated with clinical AI outputs.
The company has signed 165 health-system AI clients, including eight hospitals on the nation’s honor roll, Tangney said. Recent health-system wins included Northwestern, Penn Medicine and the University of Michigan. Doximity said all 165 clients are live in the sense that they have privacy agreements in place and their physicians can use its AI tools, though systems are at varying stages of electronic-health-record integration.
AI Search supports commercial activity
Doximity launched AI Search in late April and said the product is generating higher engagement with pharmaceutical customers. CFO Matt Sonefeldt said the company did not recognize AI Search revenue during the first quarter, but it has onboarded an initial cohort of customers across more than two dozen programs. The majority of contracted AI Search revenue to date is expected to be recognized in the fiscal third quarter.
Sonefeldt said AI Search has helped Doximity access innovation, insights-and-analytics, and search-related budgets at pharmaceutical companies, although the broader pharmaceutical spending environment remains tight. He described the environment as more stable than in prior periods.
During the call, executives said early AI Search contracts were intentionally structured with conservative inventory caps and shorter commitments of three to four months as the company protected the physician user experience and gathered customer feedback. As Doximity enters its annual upfront selling season, it expects to pursue larger and longer contracts, expand inventory across therapeutic categories, and offer more purchasing options, including category, keyword and target-list approaches.
Tangney said Doximity is currently generating more than 10 times as much revenue per AI Search query as it costs to run the service. He added that the company expects the cost of AI models to decline over time as models become more efficient. Sonefeldt said Doximity sees opportunities to improve efficiency through model optimization, capacity management, forecasting and internally developed AI tools.
The company said its AI products can also support its established pharmaceutical marketing offerings. Tangney said insights from AI Search, such as physicians’ questions about drug side effects or dosing conversions, can inform follow-up engagement through Doximity’s telehealth and other platform products.
Financial performance and customer metrics
Doximity said revenue growth was supported by pharmaceutical and hospital customers, particularly larger accounts. The company had 127 pharmaceutical and hospital customers generating more than $500,000 in trailing-12-month subscription revenue, up 7% from a year earlier. Those customers represented 83% of total revenue.
- Top 20 customer net revenue retention was 112%.
- Overall trailing-12-month net revenue retention was 107%.
- Non-GAAP gross margin was 88%, compared with 91% a year earlier.
- GAAP earnings per share were $0.13, while non-GAAP earnings per share were $0.29.
- Free cash flow was $40 million, which Doximity attributed in part to normal collection-timing variability.
The company ended the quarter with $688 million in cash equivalents and marketable securities and no debt. It repurchased $92 million of shares during the quarter and had roughly $400 million remaining under its repurchase authorization as of June 30.
Outlook reflects additional AI investment
For the fiscal second quarter, Doximity forecast revenue of $170 million to $171 million, representing 1% year-over-year growth at the midpoint. The company said the growth rate reflects a difficult comparison with the prior year’s 23% growth and only modest expected AI Search revenue in the second quarter.
For fiscal 2027, Doximity raised its revenue outlook to $671 million to $681 million, representing 5% growth at the midpoint. The higher outlook reflects first-quarter outperformance, a modest incremental increase, a more stable pharmaceutical budget environment, increased customer interaction and an expanding AI commercial pipeline, Sonefeldt said.
Doximity expects second-quarter adjusted EBITDA of $80.5 million to $81.5 million, or a 48% margin at the midpoint. Full-year adjusted EBITDA is projected at $309 million to $329 million, or a 47% margin at the midpoint.
The company said approximately 90% of its AI-related spending will support rising demand for its clinical AI suite and will be recognized in cost of revenue. As a result, Doximity expects gross margins to remain in the mid-to-high-80% range during fiscal 2027.
About Doximity (NYSE:DOCS)
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
